
Certificates Are Not Evidence: Regulators Target Product Identity and Strength
FDA issued a warning letter to Guangdong Bangze Medicine after a remote records review under section 704(a)(4). The review found reliance on unverified supplier certificates, no identity, assay or impurity testing of incoming components, incomplete finished-product testing and an ineffective








